Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich's Ataxia Clinical Trial

Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich's Ataxia Clinical Trial. PR Newswire, Press release Jan. 7, 2013, 12:01 a.m. EST

MOUNTAIN VIEW, Calif., Jan. 7, 2013 /PRNewswire via COMTEX/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia." The trial is a placebo-controlled study lasting six months, followed by an extension phase in which all subjects will receive EPI-743.

More information on study specifics is available on ClinicalTrials.gov.